Success Story: NIW Approval for Drug Delivery Research Advancing More Effective Therapies for Cancer and Chronic Diseases
Client’s Testimonial:
"I had a wonderful experience working with Chen Immigration for my EB-2 NIW petition. All the suggestions and responses that they provided were very useful and timely. I strongly recommend them to anyone looking for EB2-NIW!"
On July 17th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Associate in the Field of Drug Delivery (Approval Notice).
General Field: Drug Delivery
Position at the Time of Case Filing: Research Associate
Country of Origin: Nepal
State of Residence at the Time of Filing: Connecticut
Approval Notice Date: July 17th, 2026
Processing Time: 11 months, 17 days (Premium Processing Upgrade Requested)
Case Summary:
A recent I-140 National Interest Waiver (NIW) approval was secured for a drug delivery researcher whose work focuses on developing and characterizing innovative delivery platforms for small molecules and biologics to improve therapeutic effectiveness while reducing adverse effects in the treatment of cancer and other chronic diseases.
The client's research is dedicated to designing advanced drug delivery systems that improve how therapies are administered, enabling more precise treatment while minimizing toxicity. At the time of filing, the client, who holds a Ph.D. in pharmacy, was employed as a research associate, where the client continued investigating delivery platforms for small molecules and biologics, including research involving cancer therapies, radiotherapy, immunotherapy, and implant-based drug delivery technologies. We demonstrated that this proposed endeavor possesses substantial merit and national importance because of its potential to improve treatment outcomes for cancer and other chronic diseases that affect millions of patients.
The client's academic and professional record reflected sustained achievement in the field. Specifically:
- 8 first-authored, peer-reviewed journal articles
- 4 first-authored conference abstracts
- 195 citations to published research
- At least 4 completed peer reviews for respected scientific journals
To demonstrate that the client was well positioned to advance this important area of research, North America Immigration Law Group (NAILG) presented evidence showing that the client's publications had influenced subsequent research on nanomedicine, cancer therapeutics, and advanced drug delivery systems. Rather than treating publication and citation metrics as sufficient on their own, we explained that independent researchers had relied on the client's methodologies, experimental findings, and analytical approaches in their own investigations, reflecting meaningful recognition of the client's original contributions. We also highlighted the client's peer-review service as evidence that the scientific community trusted the client's expertise to evaluate the work of other researchers.
The petition further established that the client's proposed endeavor, to develop and characterize delivery platforms for small molecules and biologics that enhance efficacy while reducing adverse effects, addresses important public health challenges associated with cancer and other chronic diseases. We organized the evidence to show that the client's research contributes to more effective and safer therapeutic strategies while supporting continued innovation in drug delivery technologies. By combining the client's scholarly record, demonstrated influence on subsequent research, and clearly defined future research plans, we showed that the client was well positioned to continue advancing an endeavor that offers meaningful benefits to healthcare and biomedical innovation in the United States.
USCIS approved the client's I-140 National Interest Waiver petition after concluding that the evidence satisfied the NIW standard. By presenting a structured record demonstrating the national importance of the client's research, the influence of the client's scientific contributions, and the client's ability to continue advancing innovative drug delivery technologies, NAILG helped establish that waiving the job offer and labor certification requirements would benefit the United States.